Blood Test NMAP Levels in Newly Diagnosed Kidney Cancer Patients
Compares NMAP blood levels in adults with new kidney cancer and people without it.
Plain-language title generated from the registry record
Registry title: Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a newly found kidney or liver mass who plan to have surgery, and for control patients with no tumor. It compares a blood protein level (NMAP) between the two groups.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A newly found kidney or liver mass in the tumor group, with surgery planned. The control group has no tumor, based on scans and common tumor blood markers.
- Earlier treatment
- No earlier systemic or local treatment for a kidney or liver tumor.
Main reasons for not taking part
- Severe other diseases or infections that the investigators think make joining unwise
- Known or suspected other cancer
- Another cancer in the past 5 years
- Major surgery under general anesthesia within 4 weeks before screening
- Heart, lung, liver or kidney function too weak to tolerate surgery
Read by machine on 12 November 2026.
Where in China
- Xinhua Hospital Affiliated to Shanghai Jiaotong University School of MedicineShanghai, ChinaContact: Jie NA Ding, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT04113486
- Record updated
- 29 July 2026
- Original description
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.Read full original descriptionShow less
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.
Inclusion: The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers; Age ≥ 18 years old and able to provide written informed consent; Have not received any systemic or topical treatment for kidney/liver tumors; Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements.
Exclusion: The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc; Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits; The subjects is known or suspected of other malignancies; There has been another history of malignancy in the past 5 years.